Radioligand and Radiopharmaceutical Therapy: Iodine-131, Radium-223, and Lutetium-177

1. Introduction: Targeted Radiation from Unsealed Sources

Radionuclide (radiopharmaceutical) therapy delivers ionizing radiation systemically or regionally by attaching a radioactive isotope to a molecule that concentrates in tumors. Unlike external beam radiotherapy, it is not constrained by anatomy: the radiation is carried by the agent to the target. Radioiodine for thyroid cancer is the oldest and most successful example; more recently, radiolabeled peptides and antibodies have been shown in randomized trials to improve survival in prostate cancer and neuroendocrine tumors. The field is often described as «theranostics,» because imaging and therapy can use the same targeting molecule paired with different isotopes.

2. Physical Basis: Beta and Alpha Emitters

The therapeutic effect depends on the emission profile. Beta emitters (iodine-131, lutetium-177, yttrium-90) deposit energy over a range of millimeters, allowing «cross-fire» killing of nearby tumor cells. This longer range is useful for bulky, heterogeneous tumors but also irradiates adjacent normal tissue. Alpha emitters (radium-223, actinium-225) deliver high-linear-energy-transfer radiation over only a few cell diameters, producing dense DNA damage with less bystander irradiation — theoretically advantageous, though their clinical development is earlier and handling is more complex. Auger electron emitters produce very short-range, high-density damage.

3. Established Agents and Their Evidence

3.1. Thyroid Cancer

Radioiodine has been used since the 1940s to ablate thyroid remnants and treat iodine-avid differentiated thyroid cancer. It is a rare example of a systemic therapy that exploits a physiological uptake mechanism, and it is curative in many patients with appropriate disease.

3.2. Prostate Cancer: Radium-223 and Lutetium-177 PSMA

The ALSYMPCA trial showed that radium-223 improved overall survival in men with bone metastases from castration-resistant prostate cancer, establishing the first alpha-emitter with a survival benefit. The VISION trial subsequently showed that lutetium-177 PSMA-617 improved overall survival in heavily pretreated PSMA-positive metastatic castration-resistant prostate cancer, and it has become a standard option in that setting.

3.3. Neuroendocrine Tumors

Lutetium-177 DOTATATE binds somatostatin receptors and delivers beta radiation to well-differentiated neuroendocrine tumors. The NETTER-1 trial showed improved progression-free survival compared with high-dose octreotide, and it is now an established treatment for advanced, receptor-positive gastroenteropancreatic neuroendocrine tumors.

3.4. Liver Tumors

Yttrium-90 microsphere radioembolization (selective internal radiation therapy) is used for primary and metastatic liver tumors, with evidence supporting use in selected patients and as a bridging or downstaging strategy. Comparative data versus other liver-directed therapies continue to evolve.

4. Early Research and Emerging Approaches

• Actinium-225 and other alpha-emitting conjugates (for example, Ac-225 PSMA) are in early trials; alpha radiation’s short range and high potency may improve the therapeutic ratio, but toxicity and supply must be addressed.
• Combinations with immunotherapy, DNA-repair inhibitors, or chemotherapy are being studied to convert radiopharmaceutical effects into systemic responses.
• Theranostic pairs (imaging isotope plus therapeutic isotope on the same targeting ligand) are expanding the selection and dosimetry of patients likely to benefit.

5. Limitations and Toxicity

Myelosuppression is the most common dose-limiting toxicity. Organ-specific effects include renal injury (relevant to PSMA agents and peptides), salivary gland and lacrimal toxicity (PSMA agents), and, historically, an increased risk of myelodysplastic syndrome and leukemia. Alpha emitters carry additional handling and supply complexity. Efficacy depends on adequate target expression, and dosimetry — estimating radiation absorbed by tumor and normal organs — is an active area of refinement.

6. Unresolved Questions and Speculative Directions

• Optimal sequencing and combination of radiopharmaceuticals with androgen-receptor pathway inhibitors, chemotherapy, or immunotherapy is not settled. [Marked for verification.]
• Whether alpha emitters will prove clinically superior to beta emitters for solid targets is a key open question.

7. Conclusion

Radiopharmaceutical therapy is a mature and expanding field that delivers ionizing radiation through molecule-targeted carriers. It is curative in differentiated thyroid cancer, has randomized survival benefit in bone-metastatic prostate cancer (radium-223), PSMA-positive prostate cancer (lutetium-177 PSMA), and neuroendocrine tumors (lutetium-177 DOTATATE), and has established roles in liver-directed treatment. Its main limitations are myelosuppression, organ-specific toxicity, and the need for refined dosimetry. Alpha emitters, theranostic selection, and combination strategies are promising but remain earlier in development.

Sources and Key Research Centers

• National Cancer Institute — radiopharmaceutical and radioisotope therapy information.
• Society of Nuclear Medicine and Molecular Imaging (SNMMI) — guidance and dosimetry resources.
• European Association of Nuclear Medicine (EANM) — procedural guidelines and theranostics.
• Radium-223 in prostate cancer
  • Parker C, Nilsson S, Heinrich D, et al. «Alpha emitter radium-223 and survival in metastatic prostate cancer.» New England Journal of Medicine, 2013; 369(3): 213–223. DOI: 10.1056/NEJMoa1213755
• Lutetium-177 DOTATATE in neuroendocrine tumors
  • Strosberg J, El-Haddad G, Wolin E, et al. «Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors.» New England Journal of Medicine, 2017; 376(2): 125–135. DOI: 10.1056/NEJMoa1607427
• Lutetium-177 PSMA in prostate cancer
  • Sartor O, de Bono J, Chi KN, et al. «Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer.» New England Journal of Medicine, 2021; 385(12): 1091–1103. DOI: 10.1056/NEJMoa2107322
• ClinicalTrials.gov — ongoing trials of alpha emitters and radiopharmaceutical combinations (search terms: actinium-225, radioligand therapy).

Note: citation identifiers are provided where available; readers should confirm bibliographic details against the publisher’s record. This article is an editorial scientific overview and is not a medical recommendation.